HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) View Online Appendix View CVN News Brief Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JACC Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Google Scholar Articles by Bourge, R. C. PubMed Articles by Bourge, R. C.

CLINICAL RESEARCH: HEART FAILURE

Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure

The COMPASS-HF Study

Robert C. Bourge, MD^_*,1,_*, William T. Abraham, MD, FACC^,2, Philip B. Adamson, MD, FACC^,3, Mark F. Aaron, MD^,4, Juan M. Aranda, Jr, MD^||,5, Anthony Magalski, MD^¶, Michael R. Zile, MD^#,6, Andrew L. Smith, MD, FACC^_**,7, Frank W. Smart, MD^,8, Mark A. O’Shaughnessy, MD, Mariell L. Jessup, MD^,9, Brandon Sparks, MS^||||,10, David L. Naftel, PhD^_*, Lynne Warner Stevenson, MD^¶¶,11 on behalf of the COMPASS-HF Study Group

^_* Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio
Oklahoma Heart Hospital, Oklahoma City, Oklahoma
Tennessee Cardiovascular Research Institute at St. Thomas Hospital, Nashville, Tennessee
^|| Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida
^¶ Mid-America Heart Institute, Kansas City, Missouri
^# Medical University of South Carolina, Charleston, South Carolina
^_** Crawford Long Hospital/Emory University Hospital, Atlanta, Georgia
Morristown Memorial Hospital, Morristown, New Jersey
Parkview Memorial, Fort Wayne, Indiana
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
^|||| Medtronic, Inc., Minneapolis, Minnesota
^¶¶ Brigham and Women’s Hospital, Boston, Massachusetts.

Manuscript received June 7, 2007; revised manuscript received October 16, 2007, accepted October 22, 2007.

^_* Reprint requests and correspondence: Dr. Robert C. Bourge, Division of Cardiovascular Disease, 311 THT, 1900 University Boulevard, University of Alabama at Birmingham, Birmingham, Alabama 35294. (Email: bbourge{at}uab.edu).

Objectives: The purpose of this study was to determine whether a heart failure (HF) management strategy using continuous intracardiac pressure monitoring could decrease HF morbidity.

Background: Patients with HF may experience frequent decompensations that require hospitalization despite intensive treatment and follow-up.

Methods: The COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) study was a prospective, multicenter, randomized, single-blind, parallel-controlled trial of 274 New York Heart Association functional class III or IV HF patients who received an implantable continuous hemodynamic monitor. Patients were randomized to a Chronicle (Medtronic Inc., Minneapolis, Minnesota) (n = 134) or control (n = 140) group. All patients received optimal medical therapy, but the hemodynamic information from the monitor was used to guide patient management only in the Chronicle group. Primary end points included freedom from system-related complications, freedom from pressure-sensor failure, and reduction in the rate of HF-related events (hospitalizations and emergency or urgent care visits requiring intravenous therapy).

Results: The 2 safety end points were met with no pressure-sensor failures and system-related complications in only 8% of the 277 patients who underwent implantation (all but 4 complications were successfully resolved). The primary efficacy end point was not met because the Chronicle group had a nonsignificant 21% lower rate of all HF-related events compared with the control group (p = 0.33). A retrospective analysis of the time to first HF hospitalization showed a 36% reduction (p = 0.03) in the relative risk of a HF-related hospitalization in the Chronicle group.

Conclusions: The implantable continuous hemodynamic monitor-guided care did not significantly reduce total HF-related events compared with optimal medical management. Additional trials will be necessary to establish the clinical benefit of implantable continuous hemodynamic monitor-guided care in patients with advanced HF.

Abbreviations and Acronyms   CRT = cardiac resynchronization therapy   EF = ejection fraction   ePAD = estimated pulmonary artery diastolic pressure   HF = heart failure   ICD = implantable cardioverter-defibrillator   ICHM = implantable continuous hemodynamic monitor   NYHA = New York Heart Association

Related articles in JACC:

Learning the Points of COMPASS-HF: Assessing Implantable Hemodynamic Monitoring in Heart Failure Patients

John R. Teerlink
JACC 2008 51: 1080-1082. [Full Text]  

Inside This Issue of JACC

JACC 2008 51: A26. [Full Text]  

This article has been cited by other articles:

				Wanted: A Reliable COMPASS for Heart Failure Management Journal Watch Cardiology, March 26, 2008; 2008(326): 3 - 3. [Full Text]

				J. R. Teerlink Learning the points of COMPASS-HF: assessing implantable hemodynamic monitoring in heart failure patients. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1080 - 1082. [Full Text] [PDF]